drugset
drugset / Trial / NCT05506605

Switch Strategy From Etravirine (ETR) to Doravirine (DOR) in Virologically-Suppressed HIV-1 Infected Adults With ETR-Resistance

NCT05506605 ↗

Phase 4 Unknown 12 enrolled Fundacion Clinic per a la Recerca Biomédica
NaSingle-groupOpen-labelTreatment

Summary

Phase IV, open-label, single arm, unicenter and pilot study on virologically suppressed HIV infected adults with ETR resistance, to assess the efficacy of a Switch strategy from Etravirine (ETR) to Doravirine (DOR).

Timeline

Start
2022-12-12
Primary completion
2024-12
Completion
2024-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Doravirine Small molecule 100 mg —

Indications

HIV infectious disease